Gilead Sciences (GILD) Return on Capital Employed (2009 - 2026)
Gilead Sciences posted quarterly Return on Capital Employed of 21.53% for Q1 2026, up 341.0% year-on-year from 4.88% in Q1 2025, and up 0.88% on a QoQ basis from 21.34% in Q4 2025.
Gilead Sciences (GILD) has 18 years of Return on Capital Employed data on file, last reported at 21.53% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 341.0% year-over-year to 21.53%; the trailing twelve-month figure through Mar 2026 stood at 21.53% (up 341.0% YoY), and the FY2025 full-year result was 21.23%, up 1781.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 21.53%, up from 21.34% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 23.4% in Q3 2025 and bottomed at 1.94% in Q3 2024.
- The 5-year median for Return on Capital Employed is 14.92% (2023), against an average of 13.79%.
- The widest annual swing landed in 2024, when Return on Capital Employed tumbled 1444 bps; it then soared 2146 bps in 2025.
- A 5-year view of Return on Capital Employed shows it stood at 14.2% in 2022, then rose by 5 bps to 14.92% in 2023, then tumbled by 75 bps to 3.71% in 2024, then jumped by 475 bps to 21.34% in 2025, then climbed by 1 bps to 21.53% in 2026.
- The last three Return on Capital Employed figures came in at 21.53% (Q1 2026), 21.34% (Q4 2025), and 23.4% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 42.94% |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 28.18% |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 16.47% |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | -5.22% |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 15.87% |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 21.53% |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | -10.20% |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | -6.84% |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21.53% |
| Dec 31, 2025 | 21.34% |
| Sep 30, 2025 | 23.40% |
| Jun 30, 2025 | 17.94% |
| Mar 31, 2025 | 18.12% |
| Dec 31, 2024 | 3.71% |
| Sep 30, 2024 | 1.94% |
| Jun 30, 2024 | 5.79% |
| Mar 31, 2024 | 3.42% |
| Dec 31, 2023 | 14.92% |
| Sep 30, 2023 | 16.39% |
| Jun 30, 2023 | 17.60% |
| Mar 31, 2023 | 17.00% |
| Dec 31, 2022 | 14.20% |
| Sep 30, 2022 | 11.48% |
| Jun 30, 2022 | 13.04% |
| Mar 31, 2022 | 12.68% |
| Dec 31, 2021 | 17.74% |
| Sep 30, 2021 | 20.30% |
| Jun 30, 2021 | 17.02% |
| Mar 31, 2021 | 7.83% |
| Dec 31, 2020 | 7.65% |
| Sep 30, 2020 | 5.14% |
| Jun 30, 2020 | -2.03% |
| Mar 31, 2020 | 8.59% |
| Dec 31, 2019 | 8.47% |
| Sep 30, 2019 | 8.41% |
| Jun 30, 2019 | 15.60% |
| Mar 31, 2019 | 15.38% |
| Dec 31, 2018 | 15.36% |
| Sep 30, 2018 | 14.13% |
| Jun 30, 2018 | 16.38% |
| Mar 31, 2018 | 19.06% |
| Dec 31, 2017 | 22.40% |
| Sep 30, 2017 | 30.03% |
| Jun 30, 2017 | 32.61% |
| Mar 31, 2017 | 34.14% |
| Dec 31, 2016 | 37.06% |
| Sep 30, 2016 | 45.50% |
| Jun 30, 2016 | 53.07% |
| Mar 31, 2016 | 55.30% |
| Dec 31, 2015 | 53.75% |
| Sep 30, 2015 | 58.81% |
| Jun 30, 2015 | 63.04% |
| Mar 31, 2015 | 60.53% |
| Dec 31, 2014 | 58.73% |
| Sep 30, 2014 | 50.61% |
| Jun 30, 2014 | 41.86% |
| Mar 31, 2014 | 33.70% |
| Dec 31, 2013 | 28.07% |
| Sep 30, 2013 | 25.12% |
| Jun 30, 2013 | 24.77% |
| Mar 31, 2013 | 24.29% |
| Dec 31, 2012 | 23.78% |
| Sep 30, 2012 | 23.67% |
| Jun 30, 2012 | 24.48% |
| Mar 31, 2012 | 25.54% |
| Dec 31, 2011 | 30.42% |
| Sep 30, 2011 | 35.93% |
| Jun 30, 2011 | 35.40% |
| Mar 31, 2011 | 38.89% |
| Dec 31, 2010 | 43.74% |
| Mar 31, 2010 | 46.72% |
| Dec 31, 2009 | 47.40% |
| Sep 30, 2009 | 46.88% |